Welcome to our dedicated page for Neurogene SEC filings (Ticker: NGNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gene therapy breakthroughs are exciting, but decoding the filings behind them is hard. Neurogene Inc鈥檚 reports blend dense scientific data, cash-flow forecasts, and FDA pathway details that can stretch beyond 200 pages. If you have ever wondered, 鈥淗ow do I find Neurogene Inc鈥檚 quarterly earnings report 10-Q filing?鈥� or needed Neurogene Inc insider trading Form 4 transactions before market moves, you know the challenge.
Stock Titan solves it. Our AI reads every submission the moment it hits EDGAR and creates plain-English summaries so you can start understanding Neurogene Inc SEC documents with AI instead of wrestling with technical jargon. Whether it鈥檚 an 8-K announcing a pivotal trial result or a proxy outlining executive compensation, the platform links each disclosure to practical questions like cash runway, partnership terms, and pipeline milestones.
Here鈥檚 what you gain in one place:
- AG真人官方-time alerts for Neurogene Inc Form 4 insider transactions real-time and executive stock sales.
- AI-powered extracts that turn the Neurogene Inc annual report 10-K simplified into an easy read, highlighting R&D spend and risk factors.
- Side-by-side comparisons of segment data from each Neurogene Inc quarterly earnings report 10-Q filing.
- Instant context when an Neurogene Inc 8-K material events explained filing discloses new clinical data or financing.
- Concise breakdowns of the Neurogene Inc proxy statement executive compensation so you can benchmark leadership incentives.
- Deep-dive modules offering Neurogene Inc earnings report filing analysis to gauge trial funding needs.
Investors tracking early-stage biotech risk can鈥檛 afford delays. Stock Titan delivers every NGNE filing, from S-1 shelf registrations to Neurogene Inc executive stock transactions Form 4, with AI commentary that turns complexity into clarity. Spend less time searching and more time making informed decisions.
Commodore Capital LP and Commodore Capital Master LP report beneficial ownership of 427,866 shares of Neurogene Inc. common stock, representing 3.0% of the 14,269,264 shares disclosed as outstanding. The filing states the Firm acts as investment manager to Commodore Capital Master LP and that two managing partners, Michael Kramarz and Robert Egen Atkinson, exercise investment discretion over these shares. All voting and dispositive powers are reported as shared for the 427,866 shares; no sole voting or dispositive power is claimed. The filing includes a certification that the shares were not acquired to influence control of the issuer.
Neurogene Inc. (NGNE) filed a prospectus supplement to sell up to $150,000,000 of common stock through an "at the market" sales agreement with Leerink Partners dated August 11, 2025. Leerink may sell shares from time to time as sales agent for up to 3.0% commission. The prospectus uses the last reported Nasdaq sale price of $21.29 per share on August 6, 2025 as an illustrative price and estimates up to 21,314,825 shares outstanding after an assumed sale of 7,045,561 shares at that price. Net tangible book value was $273.3 million or $19.15 per share as of June 30, 2025; after the assumed sale this would be $418.5 million or $19.63 per share, implying immediate dilution of $1.66 per share to new investors. Proceeds are intended for working capital and advancing preclinical and clinical programs. The filing reiterates clinical program status: Phase 1/2 dosing for NGN-401 is complete and registrational trial activities (Embolden TM) have begun; the NGN-101 CLN5 program is not expected to move forward after an RMAT denial. The company states it is a "smaller reporting company" and highlights standard risk factors, including substantial future capital needs and volatility of its stock.
On August 11, 2025, Neurogene Inc. reported that it issued a press release announcing financial results for the quarter ended June 30, 2025 and posted an updated corporate presentation on its website. The Form 8-K attaches Exhibit 99.1 (press release) and Exhibit 99.2 (corporate presentation) and states these exhibits are being furnished, not filed, so they are not subject to Section 18 liabilities or deemed incorporated by reference. The filing text does not include the actual earnings figures; the report is signed by Christine Mikail, President and Chief Financial Officer.
FAQ
What is the current stock price of Neurogene (NGNE)?
What is the market cap of Neurogene (NGNE)?
